Form 4: Entergy director Gina Adams acquires 265 shares under director program
Rhea-AI Filing Summary
Entergy Corporation (ETR) director Gina F. Adams reported a small equity grant on 09/02/2025. The Form 4 shows Ms. Adams acquired 265 shares under Entergy's Director Stock Program at a reported price of $0. After the transaction she beneficially owns 6,510 shares. The filing was submitted on 09/03/2025 and signed under power of attorney by Daniel T. Falstad. The report is a routine disclosure of a director's equity award under a company program and contains no additional transactions or derivative positions.
Positive
- Transaction disclosed promptly: Form 4 filed the day after the transaction (filed 09/03/2025 for a 09/02/2025 acquisition).
- Acquisition under Director Stock Program: The 265-share grant is identified as part of Entergy's director compensation program, aligning director and shareholder interests.
- Clear beneficial ownership after transaction: Reporting person beneficially owns 6,510 shares following the grant.
Negative
- None.
Insights
TL;DR: A routine director equity grant was reported; no unusual trading or departures indicated.
The Form 4 discloses a director-level acquisition under the company's Director Stock Program rather than an open-market purchase, evidenced by the reported price of $0 and the explanatory note. The transaction increases the director's beneficial stake to 6,510 shares, which is documented promptly via a Form 4 filed the following day and signed by a power of attorney. For governance monitoring, this is standard compensation-related equity issuance and does not signal change in control or unusual insider trading activity.
TL;DR: The disclosure is a routine equity grant with limited investor impact given the small share amount.
The reported acquisition of 265 shares at $0 increases the director's reported holdings but represents a modest absolute change versus total outstanding shares of a large public utility. The Form 4 contains no purchases, sales, options, or derivative instruments beyond the non‑derivative grant. Timing and prompt filing are compliant with Section 16 reporting expectations.